- Capital Cube•last month
Click here to see latest analysisAcasti Pharma, Inc. reports financial results for the quarter ended May 31, 2016.HighlightsSummary numbers: Revenues of USD 0.00 million, Net Earnings of USD -2.42 million.Gross margins narrowed from -11,357.12% to -20,974.65% compared to the same period last year, operating (EBITDA) margins now -82,173.61% from -39,469.07%.Change in operating cash flow of […] (Read more...) The post Acasti Pharma, Inc. :ACST-US: Earnings Analysis: Q1, 2017 By the Numbers : July 22, 2016 appeared first on CapitalCube.
- Marketwired•last monthAcasti Announces the Election of its Directors, Change of Fiscal Year End and Other Related Matters Passed at its AGM
Acasti Pharma Inc. of new krill oil-based forms of omega-3 phospholipid therapies for the treatment of hypertriglyceridemia, announced that the nominees listed in its management proxy circular dated June ...
- Associated Press•last month
The Laval, Quebec-based company said it had a loss of 23 cents per share. The biopharmaceutical company posted revenue of $2,000 in the period. In the final minutes of trading on Monday, the company's ...
Acasti Pharma Inc. (ACST)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
|Bid||1.31 x 1400|
|Ask||12.50 x 500|
|Day's Range||1.31 - 1.36|
|52wk Range||1.20 - 3.80|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-2.17|
|Avg Vol (3m)||25,892|
|Dividend & Yield||N/A (N/A)|